NFL Biosciences Statistics

Total Valuation

NFL Biosciences has a market cap or net worth of EUR 12.42 million. The enterprise value is 10.80 million.

Market Cap	12.42M
Enterprise Value	10.80M

Important Dates

The next confirmed earnings date is Thursday, October 22, 2026.

Earnings Date	Oct 22, 2026
Ex-Dividend Date	n/a

Share Statistics

NFL Biosciences has 12.67 million shares outstanding. The number of shares has increased by 28.81% in one year.

Current Share Class	12.67M
Shares Outstanding	12.67M
Shares Change (YoY)	+28.81%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.08%
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	66,057.43
PB Ratio	40.57
P/TBV Ratio	83.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.25
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.51, with a Debt / Equity ratio of 1.90.

Current Ratio	4.51
Quick Ratio	4.20
Debt / Equity	1.90
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-272.89

Financial Efficiency

Return on equity (ROE) is -517.39% and return on invested capital (ROIC) is -253.96%.

Return on Equity (ROE)	-517.39%
Return on Assets (ROA)	-66.56%
Return on Invested Capital (ROIC)	-253.96%
Return on Capital Employed (ROCE)	-133.15%
Weighted Average Cost of Capital (WACC)	10.17%
Revenue Per Employee	47
Profits Per Employee	-829,492
Employee Count	4
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-539,779
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.33% in the last 52 weeks. The beta is 1.15, so NFL Biosciences's price volatility has been higher than the market average.

Beta (5Y)	1.15
52-Week Price Change	-18.33%
50-Day Moving Average	1.01
200-Day Moving Average	1.15
Relative Strength Index (RSI)	51.66
Average Volume (20 Days)	88,538

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NFL Biosciences had revenue of EUR 188 and -3.32 million in losses. Loss per share was -0.26.

Revenue	188
Gross Profit	-2.52M
Operating Income	-3.87M
Pretax Income	-3.86M
Net Income	-3.32M
EBITDA	-3.79M
EBIT	-3.87M
Loss Per Share	-0.26

Full Income Statement

Balance Sheet

The company has 2.20 million in cash and 582,585 in debt, with a net cash position of 1.62 million or 0.13 per share.

Cash & Cash Equivalents	2.20M
Total Debt	582,585
Net Cash	1.62M
Net Cash Per Share	0.13
Equity (Book Value)	306,144
Book Value Per Share	0.02
Working Capital	2.65M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	86,402
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-2,059,909.04%
Pretax Margin	-2,051,992.55%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NFL Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-28.81%
Shareholder Yield	-28.81%
Earnings Yield	-26.72%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NFL Biosciences has an Altman Z-Score of -1.09. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.09
Piotroski F-Score	n/a